Cargando…

Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation

BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease closely linked to cardiovascular disease (CVD). This study aims to investigate the connection between early-stage NAFLD and atherosclerosis, as well as the correlation between liver fibrosis and coronary heart di...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Si-hua, Zhou, Xiao-li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681951/
https://www.ncbi.nlm.nih.gov/pubmed/37952443
http://dx.doi.org/10.1016/j.clinsp.2023.100301
_version_ 1785150872431362048
author Tan, Si-hua
Zhou, Xiao-li
author_facet Tan, Si-hua
Zhou, Xiao-li
author_sort Tan, Si-hua
collection PubMed
description BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease closely linked to cardiovascular disease (CVD). This study aims to investigate the connection between early-stage NAFLD and atherosclerosis, as well as the correlation between liver fibrosis and coronary heart disease while exploring underlying inflammatory mechanisms. METHODS: In this retrospective study, the authors analyzed data from 607 patients who underwent both coronary computed tomography angiography (CCTA) and abdominal ultrasonography (US). Logistic regression was utilized to examine the association between NAFLD and atherosclerosis, while mediation analysis was conducted to explore whether inflammatory markers mediate the link between liver fibrosis and coronary artery disease. RESULTS: Among the 607 patients included, 237 (39.0 %) were diagnosed with NAFLD through ultrasonography. After adjusting for traditional cardiovascular risk factors, ALT, and AST, NAFLD demonstrated a significant correlation with carotid intimal thickening (1.58, 95 % CI 1.04‒2.40; p = 0.034) and non-calcified plaque (1.56, 95 % CI 1.03‒2.37; p = 0.038). Additionally, fibrosis predictive markers, including FIB-4 > 1.3 (1.06, 95 % CI 2.30‒5.00; p = 0.035) and APRI (6.26, 95 % CI 1.03‒37.05; p = 0.046), independently correlated with coronary heart disease after adjusting for cardiovascular risk factors. Conversely, among systemic inflammatory markers, only the neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory response index (SIRI) are independently associated with coronary heart disease. ROC curve analysis indicated that combining predictive fibrosis markers or inflammatory markers with traditional cardiovascular risk factors enhanced the predictive accuracy for coronary heart disease. Mediation analysis revealed that NLR fully mediated the effect of liver fibrosis on coronary heart disease. CONCLUSION: NAFLD is associated with carotid intimal thickening and non-calcified plaque, suggesting an increased cardiovascular risk. Furthermore, liver fibrosis independently increases the risk of coronary heart disease in the early-stage NAFLD population, and inflammation may play a fully mediating role in the effect of liver fibrosis on coronary heart disease. Early intervention is crucial for NAFLD patients to mitigate future major adverse cardiovascular events.
format Online
Article
Text
id pubmed-10681951
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
record_format MEDLINE/PubMed
spelling pubmed-106819512023-11-30 Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation Tan, Si-hua Zhou, Xiao-li Clinics (Sao Paulo) Original Articles BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease closely linked to cardiovascular disease (CVD). This study aims to investigate the connection between early-stage NAFLD and atherosclerosis, as well as the correlation between liver fibrosis and coronary heart disease while exploring underlying inflammatory mechanisms. METHODS: In this retrospective study, the authors analyzed data from 607 patients who underwent both coronary computed tomography angiography (CCTA) and abdominal ultrasonography (US). Logistic regression was utilized to examine the association between NAFLD and atherosclerosis, while mediation analysis was conducted to explore whether inflammatory markers mediate the link between liver fibrosis and coronary artery disease. RESULTS: Among the 607 patients included, 237 (39.0 %) were diagnosed with NAFLD through ultrasonography. After adjusting for traditional cardiovascular risk factors, ALT, and AST, NAFLD demonstrated a significant correlation with carotid intimal thickening (1.58, 95 % CI 1.04‒2.40; p = 0.034) and non-calcified plaque (1.56, 95 % CI 1.03‒2.37; p = 0.038). Additionally, fibrosis predictive markers, including FIB-4 > 1.3 (1.06, 95 % CI 2.30‒5.00; p = 0.035) and APRI (6.26, 95 % CI 1.03‒37.05; p = 0.046), independently correlated with coronary heart disease after adjusting for cardiovascular risk factors. Conversely, among systemic inflammatory markers, only the neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory response index (SIRI) are independently associated with coronary heart disease. ROC curve analysis indicated that combining predictive fibrosis markers or inflammatory markers with traditional cardiovascular risk factors enhanced the predictive accuracy for coronary heart disease. Mediation analysis revealed that NLR fully mediated the effect of liver fibrosis on coronary heart disease. CONCLUSION: NAFLD is associated with carotid intimal thickening and non-calcified plaque, suggesting an increased cardiovascular risk. Furthermore, liver fibrosis independently increases the risk of coronary heart disease in the early-stage NAFLD population, and inflammation may play a fully mediating role in the effect of liver fibrosis on coronary heart disease. Early intervention is crucial for NAFLD patients to mitigate future major adverse cardiovascular events. Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 2023-11-11 /pmc/articles/PMC10681951/ /pubmed/37952443 http://dx.doi.org/10.1016/j.clinsp.2023.100301 Text en © 2023 HCFMUSP. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Articles
Tan, Si-hua
Zhou, Xiao-li
Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
title Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
title_full Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
title_fullStr Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
title_full_unstemmed Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
title_short Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
title_sort early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681951/
https://www.ncbi.nlm.nih.gov/pubmed/37952443
http://dx.doi.org/10.1016/j.clinsp.2023.100301
work_keys_str_mv AT tansihua earlystagenonalcoholicfattyliverdiseaseinrelationtoatherosclerosisandinflammation
AT zhouxiaoli earlystagenonalcoholicfattyliverdiseaseinrelationtoatherosclerosisandinflammation